See more : Mangalam Drugs & Organics Limited (MANGALAM.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Onconetix, Inc. (ONCO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Onconetix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Envela Corporation (ELA) Income Statement Analysis – Financial Results
- Trisura Group Ltd. (TSU.TO) Income Statement Analysis – Financial Results
- DNB Bank ASA (DNBBY) Income Statement Analysis – Financial Results
- Omer-Decugis & Cie SA (ALODC.PA) Income Statement Analysis – Financial Results
- Arteris, Inc. (AIP) Income Statement Analysis – Financial Results
Onconetix, Inc. (ONCO)
About Onconetix, Inc.
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 58.47K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.19M | 6.75K | 4.89K | 3.06K | 573.00 |
| Gross Profit | -1.13M | -6.75K | -4.89K | -3.06K | -573.00 |
| Gross Profit Ratio | -1,927.93% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.95M | 4.13M | 1.33M | 524.91K | 60.17K |
| General & Administrative | 14.77M | 9.35M | 2.09M | 1.10M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.77M | 9.35M | 2.09M | 1.10M | 819.49K |
| Other Expenses | 18.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 33.72M | 13.48M | 3.42M | 1.62M | 879.66K |
| Cost & Expenses | 34.91M | 13.48M | 3.42M | 1.62M | 880.23K |
| Interest Income | 0.00 | 0.00 | 0.00 | 22.60K | 58.32K |
| Interest Expense | 671.63K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 43.94K | 6.75K | 4.89K | 3.06K | 573.00 |
| EBITDA | -36.71M | -13.54M | -3.41M | -1.62M | -821.34K |
| EBITDA Ratio | -62,784.10% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.03M | -13.48M | -3.42M | -1.62M | -880.23K |
| Operating Income Ratio | -61,634.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.39M | 61.41K | 0.00 | 22.60K | 58.32K |
| Income Before Tax | -37.42M | -13.42M | -3.42M | -1.60M | -821.92K |
| Income Before Tax Ratio | -64,008.02% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -12.59K | -61.41K | -4.00 | -203.24K | -3.00 |
| Net Income | -37.41M | -13.42M | -3.42M | -1.60M | -821.92K |
| Net Income Ratio | -63,986.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.19 | -1.09 | -0.31 | -0.14 | -0.07 |
| EPS Diluted | -2.19 | -1.09 | -0.31 | -0.14 | -0.07 |
| Weighted Avg Shares Out | 17.11M | 12.27M | 10.91M | 11.05M | 11.05M |
| Weighted Avg Shares Out (Dil) | 17.11M | 12.27M | 10.91M | 11.05M | 11.05M |
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
Crude Oil Rises; Onconetix Shares Spike Higher
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
Why Is Onconetix (ONCO) Stock Up 37% Today?
Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds
Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds
Source: https://incomestatements.info
Category: Stock Reports